SGX Market Updates

Singapore Listed Healthcare Providers Expanding Across Asia


PUBLISHED ON |

17 January 2018

  • Singapore’s largest capitalised stocks of the Healthcare Providers and Services Industry have announced and affirmed several expansion plans in 2017. The majority of these stocks are expanding services in Greater China, South East Asia or at home in Singapore.

  • IHH Healthcare Bhd, Raffles Medical, Health Management Intl, TalkMed and Q&M Dental are the five largest capitalised companies of the Healthcare Providers & Services Industry, and are pursuing regional expansion plans.

  • The 17 SGX-listed stocks of the Healthcare Providers & Services Industry and two REITs investing in properties providing healthcare services averaged a 2.4% gain in the YTD, following a median gain of 8.9% in 2017.




Demand for healthcare services continues to increase across the world with more people and people living longer. Longevity and population growth has particularly been on the rise in Asia, which has directionally correlated with secular expenditure on healthcare services.

As discussed here the IMF maintain that East Asia’s (includes China, Hong Kong, Japan, North and South Korea, Mongolia, Macao and Taiwan) population is ageing faster than anywhere else in the world, with its old-age dependency ratio roughly tripling by 2050.



Expanding Existing Healthcare Services

The majority of the 17 stocks that make up the GICS® Healthcare Providers & Services Industry announced or affirmed expansion plans during 2017. For instance the five largest capitalised stocks of the Healthcare Providers & Services Industry not including the Business Trust or REITs have announced the following expansions:

  • IHH Healthcare Berhad (“IHH”) opened new hospitals in Hong Kong and Istanbul in March 2017. When reporting its most recent financials, IHH noted it was making further headway in the important market of Greater China as its next home market, in addition to maintaining a strong pipeline of expansion projects in its existing home markets.
  • Raffles Medical Group (“RMG”) estimates that the Raffles Hospital Extension will contribute an additional 220,000 square feet of space, thereby almost doubling the space available for clinical services in the integrated medical complex. In August 2017, RMG opened two new in-house clinics in Dover and Tampines, then re-opened its Northpoint City clinic in September 2017 after the mall’s retrofitting. RMG has also been opening new clinics at Changi Airport, where it has been the at the designated medical group since 1990. As noted with the 3QFY17 results, RMG’s construction of the 700-bed RafflesHospital Chongqing and 400-bed RafflesHospital Shanghai were progressing according to plan. These hospitals are targeted to be operational by second half 2018 and second half 2019 respectively.
  • Health Management International (“HMI”) highlighted in its 1QFY18 results, that it was increasing bed capacities at its key facilities. HMI is currently increasing bed capacity from 266 beds to 300 beds in FY18 with eventual capacity of 340 beds at the Mahkota Medical Centre. At the Regency Specialist Hospital, HMI is increasing bed capacity from 166 beds to 200 beds in FY18; and planning to build an extension block in order to become a 380-bed tertiary hospital with capacity to expand to an eventual 500-bed hospital.
  • TalkMed highlighted an intention to use its Stem Med holdings to explore business opportunities in Indonesia in the areas of operation of cellular laboratories and storage facilities and cellular therapeutics clinics. As noted in its 3QFY17 results, by virtue of its 60% interest in Stem Med, TalkMed holds a 54% stake of Stem Med Indonesia Pte. Ltd which was incorporated in March 2017. The principal activities of Catalist–listed TalkMed are the provision of medical oncology services and stem cell transplants services.
  • Q&M Dental has added two dental outlets in Singapore and five dental outlets in Malaysia over the 12 months period through to 30 September 2017. In Singapore the Group has initiated a strategy of intensive organic growth of its dental clinics in Singapore. It will expand its team of dentists to support the future growth of its operation in Singapore. The Group is also closely monitoring the Malaysian economy with a view of further expansion into Malaysia and seeking opportunities for the acquisition of larger and established dental institutions and dental supplies manufacturers in PRC.

Beyond the five largest capitalised companies, there are more instances of Healthcare providers expanding regional services. Two weeks ago Cordlife Group signed a sale and purchase agreement (click here) to acquire full control of HealthBaby Biotech (Hong Kong) Co., Limited in a move that will expand its presence in the private cord blood banking industry in Hong Kong and Macau. ISEC Healthcare have noted it is expanding into the Asia Pacific region acquire assets, businesses and companies and has identified China, Indonesia, Myanmar and Vietnam as markets with growth potential.

Expanding in Singapore, Healthway Medical Corp announced with its 3QFY17 the Group setup a new Gastroenterology clinic in November 2017 - as part of its endeavour to expand its clinic network and provide better patient care. Singapore Medical Group (“SMG”) have noted that it has have brought two O&G specialists on board and will continue to hire additional specialists in the near-term. Additionally, to meet the intense demand for its diagnostic imaging services, SMG has commenced the construction of a new diagnostics centre at Novena Medical Centre.

Also expanding in Singapore, In July 2017, Singapore O&G extended its services through the offering of maiden general paediatrics and adolescent medicine services. With the new Paediatrics segment, it allows the Group to continue to take care of its existing patients and their newborns. HC Surgical Specialists announced on 2 January (click here) it had entered into a sale and purchase agreement to acquire 51.0% of the total issued and paid-up share capital of HMC Medical Pte. Ltd. for a total purchase consideration of S$673,000. HMC Medical Pte. Ltd. currently operates a clinic at Upper Thomson Road, where the Group has no presence, thereby increasing the Group’s reach and market share.



Recent Performances of the Industry

SGX lists 17 stocks that make up the GICS® Healthcare Providers & Services Industry and the two Real Estate Investment Trusts (REITs) investing in properties providing healthcare services. These two REITs are ParkwayLife REIT and First REIT. Together the 19 securities averaged a 2.4% gain in the year thus far following on from a median gain of 8.9% in 2017.



Total Returns of GICS® Healthcare Providers & Services Industry, ParkwayLife REIT & First REIT

Source: StockFacts, Bloomberg (Data as of 16 January 2018)



Note the Median measure is used for comparative measures in this instance due to the impact of a 150% gain by OUE Lippo Healthcare (“OUELH”) on the average performance which stood at 17.3%. Catalist-listed OUELH is principally involved in development and management of healthcare and related facilities in Japan and China. The company seeking to expand its healthcare portfolio across China, Japan and Southeast Asia and on 10 January announced (click here) a proposed placement of 562.5 million new ordinary shares to ITOCHU Corporation.



Comparative Performances & Latest Financials

As discussed above expansions of services were achieved organically and in multiple instances, non-organically through acquisitions, joint ventures or collaborations. The performances of the 17 SGX-listed stocks that represent the GICS® Health Care Providers and Services Industry and relevant two REITs are tabled below. To see more details on each stock below in SGX StockFacts click on the stock name.

Name SGX
Code
Market Cap
S$m
Last Price
S$
YTD
Total Return
(%)
2017
Total Return
 (%)
5 Year
Total Return
(%)
Dividend Yield
 %
Latest Financial Results
IHH Healthcare Q0F 16,314 1.970 1.5 -8.9 43.5 0.5 Click Here
Raffles Medical Group BSL 1,966 1.090 -2.7 -20.5 20.0 1.8 Click Here
Parkway Life REIT C2PU 1,773 2.940 -1.7 33.2 64.9 4.6 Click Here
First REIT AW9U 1,092 1.410 1.4 17.1 81.0 6.1 Click Here
TalkMED Group 5G3 900 0.685 0.7 36.6 N/A 2.8 Click Here
RHT Health Trust RF1U 662 0.830 -1.2 -5.8 70.8 5.7 Click Here
Health Management 588 566 0.695 5.3 4.1 507.3 0.5 Click Here
Q & M Dental Group QC7 517 0.645 4.9 -12.2 159.8 2.2 Click Here
Singapore Medical Group 5OT 263 0.590 2.6 32.2 379.4 N/A Click Here
Healthway Medical Corp 5NG 254 0.057 5.6 63.6 -39.4 N/A Click Here
OUE Lippo Healthcare 5WA 239 0.140 12.0 150.0 N/A N/A Click Here
Cordlife Group P8A 200 0.790 0.0 -18.9 64.9 0.6 Click Here
Clearbridge Health 1H3 197 0.425 19.7 N/A N/A N/A N/A
Singapore O&G 1D8 195 0.405 -8.0 -23.2 N/A 3.4 Click Here
ISEC Healthcare 40T 163 0.315 0.0 8.9 N/A 1.6 Click Here
HC Surgical Specialists 1B1 106 0.710 1.4 18.5 N/A 2.5 Click Here
TechComp Holdings T43 81 0.295 5.4 27.3 -6.0 N/A Click Here
Aoxin Q&M Dental Group 1D4 74 0.200 -4.8 N/A N/A N/A Click Here
AsiaMedic 505 25 0.064 3.2 -7.5 -48.8 N/A Click Here
Median 1.4 8.9 64.9 2.4
Average 2.4 17.3 108.1 2.7

Source: StockFacts, Bloomberg (Data as of 16 January 2018).
Note performances are not provided in the above table if the company debuted during the relevant timeframe.



The most recent addition to the segment was Clearbridge Health which listed on Catalist raising S$24.6 million and opening with market capitalisation of S$134.7 million on 18 December 2017. The stock ended yesterday at 42.5 cents, 51.8% higher than the IPO price of 28 cents. Clearbridge Health specialises in the delivery of precision medicine in Asia in addition to providing laboratory and Health Care services. Its precision medical technology businesses include Clearbridge BioPhotonics which develops the next generation microscope technology; and Clearbridge BioMedics, which developed the ClearCell® FX System - one of the world’s first fully automated cell retrieval systems.



Of the stocks tabled above, 13 currently maintain Price-to-Earnings (P/E) ratios, with an average P/E of 31x and median P/E of 25x. The five year average P/E for 10 of the stocks is 29x with a median P/E of 23x. P/E ratios and history for the respective stocks can be found in SGX StockFacts (click here).







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement